|Bid||145.00 x 800|
|Ask||0.00 x 3200|
|Day's Range||151.01 - 152.21|
|52 Week Range||98.23 - 160.25|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||43.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Masimo , a global leader in innovative noninvasive monitoring technologies, today announced it has closed on a strategic investment with TNI medical AG , a privately held, commercial-stage medical device company headquartered in Würzburg, Germany.
Masimo announced today that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and blood administration protocol using two Masimo measurements: noninvasive, continuous hemoglobin and pleth variability index .1 To evaluate the impact of the implementation, they collected data on transfusions and mortality ...
Masimo announced today the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients . With this clearance, the benefits of SpHb are available for patients of all ages in CE mark countries.
Masimo announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin m
Masimo announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ to serve as a noninvasive indicator of the arterial partial pressure of oxygen during general anesthesia, to help avoid hyperoxia.1 ORi is an index of oxygenation in the moderate hyperoxic region .
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions.
Masimo announced today that in a study recently published in Anesthesia & Analgesia, researchers investigated the incidence of isoelectric electroencephalogram events in infants and young children undergoing scheduled surgery requiring general anesthesia.1 To assess the prevalence of these events, the researchers used Masimo SedLine® brain function monitoring, available on the Root® Patient Monitoring ...
Masimo announced today that O3® Regional Oximetry has received FDA clearance for use on neonatal and infant patients . O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicative of the oxygen in the brain.
NuVision to Deploy Masimo SET®, Root® with Radical-7®, NomoLine® Capnography, and Patient SafetyNet™ at Four Locations
Masimo announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of
Masimo is hosting an Investor Day at its headquarters in Irvine today, which will include presentations by Chairman and Chief Executive Officer Joe Kiani and other members of the executive team.
Masimo announced today FDA 510 clearance of Radius PPG, a tetherless sensor solution powered by Masimo SET® that represents a significant breakthrough in patient monitoring.
Masimo today announced that its management is scheduled to present at the UBS Global Healthcare Conference at the Grand Hyatt New York on Tuesday, May 21, 2019 at 2:00 p.m.
Masimo announced today that after a decade of developing and testing its comprehensive, scalable, and customizable continuous early warning score, with the aid of leading expert clinicians around the world, it is releasing Halo ION™.
Masimo (MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI®) module for the Masimo Root® Patient Monitoring and Connectivity Hub, the first commercially available result of a Masimo Open Connect® (MOC) third-party partnership, between Mdoloris and Masimo. Masimo’s unique approach to medical technology integration through Masimo Open Connect partnerships addresses some of the major barriers to new technology adoption in patient monitoring.
Masimo announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure cerebral oxygenation in a large cohort of healthy volunteers, using Masimo O3® Regional Oximetry, to establish a normal range of values and investigate the relationship between cerebral oxygenation and other physical ...
Masimo today announced that its management is scheduled to present at the 18th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 9, 2019 at 12:50 p.m.
Masimo announced today FDA clearance of the Rad-67™ Pulse CO-Oximeter® with Spot-check Next Generation SpHb® monitoring technology and the rainbow® DCI®-mini Reusable Sensor.
Non-profit Pennsylvania Network Is Expanding Use of Masimo Patient SafetyNet™, Root® with Radius-7® and Vital Signs Check to Almost 500 Beds Across 10 Hospitals
Masimo today announced that its management is scheduled to present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on Wednesday, March 13, 2019 at 4:50 p.m.